Indiana Clinical and Translational Sciences Institute

印第安纳临床与转化科学研究所

• 批准号: 9283643
• 负责人: Scott C. Denne
• 金额: $ 69.1万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-26 至 2018-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9283643
• 关键词: Award; Clinical Research; Clinical Sciences; Development; Environment; Evaluation; Health; Health Benefit; Health Personnel; Home environment; Human; Human Subject Research; Indiana; Institutes; Institution; Instruction; Leadership; Mission; Private Sector; Process; Research; Research Infrastructure; Research Personnel; Research Project Grants; Research Support; Research Training; Resources; Services; Structure; Technology; Testing; Training; Training Programs; Training and Education; Translational Research; Universities; Vision; career; career development; catalyst; empowered; improved; informatics infrastructure; innovation; novel; programs; public-private partnership; success; tool; translational scientist

The Indiana Clinical and Translational Sciences Institute (CTSI) was created in 2008 at the crest of a wave of transformation of the three research universities in Indiana and has become a flagship catalyst for the state's biomedical Initiatives. The mission of the Indiana CTSI is to be an integrated home for clinical and translational research that creates a shared, investigator-friendly Institutional environment and provides easily accessible resources, services, and training to conduct the highest-quality research dedicated to improving human health across Indiana and beyond. The Four Specific Aims of the Indiana CTSI are: Aim I. Implement an Indiana roadmap for building the ideal research environment and collaborative platforms to conduct innovative research using our excellent multi-institutional, public-private partnerships throughout the state of Indiana and beyond by bringing together all three major research universities, Indiana, Purdue and Notre Dame, the state's key health care provider partners, private sector and corporate entities, and local and state agencies to create the infrastructure. Aim II. Further develop our successful Indiana CTSI established with the previous award into an "integrated home" that supports the careers and research projects of translational scientists and trainees through a streamlined structure, empowered leadership and administration, coordinated partner institution resources,.robust informatics infrastructure, innovative project development teams, and continuous evaluation and process improvement Aim III. Promote utilization of our innovative services and a well-tested network of resources and technologies in order to catalyze high-quality, efficient, and safe clinical and translational research. We have created Project Assistance and Resources for Translational Scientists (PARTS) suite of both established and new research support services and resources, a statewide network of technology cores, and a coordinated human subject research services and facilities. Aim IV. Extend our success in statewide education and training of clinical and translational research workforce through our Career development. Education and Research Training (CERT) suite of programs that includes successful existing programs, new training programs, and novel educational tools. RELEVANCE (See instructions): The Indiana Clinical and Translational Sciences Institute (CTSI) was created in 2008 as a statewide institute by the partnership of three research universities in Indiana (Indiana, Purdue and Notre Dame) and has become an essential resource for the state's biomedical initiatives. Here we describe its innovative vision, its impact, and its success in creating public-private partnerships to benefit the health and economy of the state.

印第安纳临床与转化科学研究所（CTSI）成立于2008年

项目成果

Harvest tissue source does not alter the protective power of stromal cell therapy after intestinal ischemia and reperfusion injury.

• DOI: 10.1016/j.jss.2016.05.006
• 发表时间: 2016-08
• 期刊: JOURNAL OF SURGICAL RESEARCH
• 影响因子: 2.2
• 作者: Jensen, Amanda R.;Manning, Morenci M.;Khaneki, Sina;Drucker, Natalie A.;Markel, Troy A.
• 通讯作者: Markel, Troy A.

Leveraging Social Networking Sites for an Autoimmune Hepatitis Genetic Repository: Pilot Study to Evaluate Feasibility.

• DOI: 10.2196/jmir.7683
• 发表时间: 2018-01-18
• 期刊: Journal of medical Internet research
• 影响因子: 7.4
• 作者: Comerford M;Fogel R;Bailey JR;Chilukuri P;Chalasani N;Lammert CS
• 通讯作者: Lammert CS

Quality versus quantity: Determining real-world social functioning deficits in schizophrenia.

• DOI: 10.1016/j.psychres.2021.113980
• 发表时间: 2021-07
• 期刊: Psychiatry research
• 影响因子: 11.3
• 作者: Abel DB;Salyers MP;Wu W;Monette MA;Minor KS
• 通讯作者: Minor KS

Social functioning in schizophrenia: Comparing laboratory-based assessment with real-world measures.

• DOI: 10.1016/j.jpsychires.2021.04.039
• 发表时间: 2021-06
• 期刊: Journal of psychiatric research
• 影响因子: 4.8
• 作者: Abel DB;Minor KS
• 通讯作者: Minor KS

Mild vs. moderate: How behavioral speech measures predict metacognitive capacity across different levels of formal thought disorder.

轻度与中度：行为言语测量如何预测不同程度的正式思维障碍的元认知能力。

• DOI: 10.1016/j.jpsychires.2022.11.013
• 发表时间: 2023
• 期刊: Journal of psychiatric research
• 影响因子: 4.8
• 作者: Myers,EvanJ;Abel,DanielleB;Hardin,KathrynL;Bettis,RobertJ;Beard,AshlynnM;Salyers,MichelleP;Lysaker,PaulH;Minor,KyleS
• 通讯作者: Minor,KyleS